Home Medical Devices Next-Generation Gynecological Cancer Diagnostics Market Size, Trends, Share, to 2030

Next-Generation Gynecological Cancer Diagnostics Market Size, Share & Trends Analysis Report By Technology (Next-Generation Sequencing, qPCR & Multiplexing, Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays, DNA Microarrays), By Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer), By Function (Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRMD2096DR
Last Updated : Sep 05, 2022
Author : Straits Research
Starting From
USD 1850
Buy Now

Market Overview

The global next-generation gynecological cancer diagnostics market size was valued at USD 2.18 billion in 2021. It is expected to reach USD 5.45 billion by 2030, growing at a CAGR of 10.68% during the forecast period (2022–2030).

Cancers of the uterus, ovary and cervical cervix are the most common types of gynecological malignancies in females worldwide. Cervical cancer ranks as the fourth most common cancer in women. Gynecological cancers result from genomic aberrations controlled by epigenetic factors, acquired, and inherited mutations, and transcriptional deviations. These factors combine to cause cancer. A thorough understanding of gynecologic cancers' genomic and molecular framework is required to develop effective biomarkers for detection and prevention, molecular profiling, and personalized treatment strategies.

In the past, the genetic analysis of gynecological cancers was performed using a technique known as Sanger sequencing, which involved the examination of tiny, individual fragments of deoxyribonucleic acid (DNA). Deciphering the molecular profile of gynecological cancers has been significantly aided by advances in molecular genetic testing such as next-generation sequencing, microarray, and polymerase chain reaction. These tests have been among the most important contributors.


Market Dynamics

Market Driving Factors

Increasing Prevalence of Lifestyle-Related Diseases to Support Market Growth

It is anticipated that the demand for next-generation cancer diagnostic tests will be driven by the increasing prevalence of oncology diseases and the hectic lifestyle that has become stressful due to the consumption of full drinks and smoking. These tests are anticipated to make an early diagnosis of a variety of cancers possible and make it possible to provide an accurate prognosis of the disease's progression. As a result, the development of this industry segment is anticipated to be positively influenced throughout the forecast period.

Creation and Continuous Improvement of New Product Offerings to Propel Growth

This market is anticipated to benefit significantly from several large entities' development and the introduction of new product offerings, the accelerated development of companion diagnostics, and their implementation in delivering personalized and advanced genomic medicine. The market is characterized by potentially high-value avenues and opportunities for growth throughout the forecast period. 

Market Restraining Factors

Inability to Accept the Diagnosis Method to Restrict Market Growth

As many genes are studied, some unexpected results may be discovered, making NGS technology a significant challenge in discovering variants without clinical significance. These findings may include risk factors for other diseases or variants that have not yet been formally classified. Molecular pathologists and clinical geneticists are needed to determine the pathogenicity of the variants that have been identified and distinguish between those that are pathogenic and those that are benign. The lack of clarity and uncertainty caused by the results is extremely difficult for families. Because of their difficult life circumstances, many of these individuals and families are already dealing with serious mental health issues. Counselors and other medical professionals face difficulties with the information provided by multiplex testing and VUS. As a result, patients with limited genetic knowledge face an even more significant challenge.

Key Market Opportunities

Development of More Accurate Laboratory Tests to Boost Market Opportunities

It is expected that the development of diagnostic laboratories and the implementation of integrated and automated laboratory systems will increase demand for advanced workflow systems and revenue generation over the forecast period. In addition, the transition from traditional laboratory testing to rapid point-of-care testing will support market expansion due to the anticipated commercialization of a range of technologically advanced products, including diagnostic kits, instruments, and reagents. This will be the case because of the shift from traditional laboratory testing to rapid point-of-care testing. Because of factors like these, there will be a lot of opportunities available to manufacturers in the market.

Study Period 2018-2030 CAGR 10.68%
Historical Period 2018-2020 Forecast Period 2022-2030
Base Year 2021 Base Year Market Size USD 2.18 Billion
Forecast Year 2030 Forecast Year Market Size USD 5.45 Billion
Largest Market North America Fastest Growing Market Asia Pacific
Talk to us
If you have a specific query, feel free to ask our experts.

Regional Analysis

The global next-generation gynecological cancer diagnostics market has been studied across North America, Europe, Asia-Pacific, and LAMEA. 

North America dominates the global next-generation gynecological cancer diagnostics market during the forecast period. It is anticipated that the market for cervical cancer diagnostics in North America will record profitable growth throughout the forecast period. This results from establishing various cancer care programs to assist lower-income demographics. The National Breast and Cervical Cancer Early Detection and Education Program (NBCCEDP) allows the Centers for Disease Control and Prevention (CDC) to help low-income, underinsured or uninsured access to timely cervical and breast cancer screening `treatment and diagnostic services. The program will also offer patient navigation services, assisting patients in overcoming obstacles and gaining convenient access to high-quality medical care.

Asia-Pacific will record significant growth in the Next-generation gynecological cancer diagnostics market during the forecast period. It is anticipated to be one of the regions with the highest growth rate in this industry, and its growth is expected to occur at a profitable rate. A largely untapped market base, which has shown technological advancement in healthcare research over the latter half of the previous decade, is one of the factors accounting for faster growth. Throughout the forthcoming forecast period, it is anticipated that significantly increased investments in healthcare research and economic development in these regions will, in turn, enhance the market potential.

There is a good chance that the market will experience significant growth in LAMEA. The market growth in these regions is fueled by increased awareness of various advanced technologies and procedures.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports


Segmental Analysis

The global market for next-generation gynecological cancer diagnostics has been divided into Type and Application.

Based on product type, it is anticipated that the pap smear segment will contribute significantly to the market's overall growth during the forecast period. The tests are most commonly used to determine whether or not cancerous or precancerous cells are present on the cervix, and they are one of the most widely recommended screening procedures for the disease. The American Cancer Society suggests that people begin screening at the age of 25, and they should follow their recommendations. In addition, it is recommended that women who are HIV positive and have a weakened immune system due to chemotherapy or an organ transplant undergo testing more frequently. Due to these factors, the demand for pap tests is expected to increase throughout the forecast period.

Based on the application, it is anticipated that the diagnostic center segment will account for a considerable portion of the overall market during the forecast period. This can largely be attributed to the availability of cancer specialists trained to utilize the most cutting-edge techniques for diagnosing cervical cancers. In addition, women who exhibit signs and symptoms of cervical cancer and attend one of these centers are allowed to participate in various diagnostic tests, such as pap tests and HPV tests.

Market Size By Technology

Market Size By Technology
  • Next-Generation Sequencing
  • qPCR & Multiplexing
  • Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
  • Protein Microarrays
  • DNA Microarrays

  • Impact of covid-19

    Covid-19 had some profound adverse impacts on the global advanced ceramics market.

    COVID-19 spread across the world from China, making the whole world stand still and to a complete lockdown situation. Covid-19 is an infectious disease that was caused by a newly discovered coronavirus. During the time, the fatality rate among the population above 40 was also high globally. The disease causes severe illness for people suffering from medical conditions like diabetes, cardiovascular disease, chronic respiratory disease, etc.

    Considering the situation during that time, it was declared a pandemic which led to numerous countries, including the major economies like China, the United States, India, and others, implementing lockdowns which adversely affected the global economy.

    In the first two quarters of 2020, the economic and industrial operations temporarily halted. Almost every manufacturing unit where advanced ceramics is used, such as electrical and electronics, transportation, industrial, chemical, and other End-user Industries (except medical), reduced their manufacturing capacities due to the lack of workers. The lockdown implemented put a halt to global supply chains. This resulted in repercussions in terms of both production and demand for advanced ceramics.

    Market Recovery Timeline and Challenges

    With time the lockdowns were uplifted, and relaxation was made to the public. Gradually, the economy picked up the pace and started its operations, bringing the demand in the global advanced ceramics market and increasing among various industries. As the situation improved during the initial months of 2021, the economies also strengthened their fiscal policies and initiated their development process; the end-user industries began their activities, bringing the overall ceramics market back on track.


    List of key players in Next-Generation Gynecological Cancer Diagnostics Market

    1. Agilent Technologies, Inc.
    2. ARUP Laboratories
    3. BGI Genomics
    4. CENTOGENE N.V.
    5. F. Hoffmann-La Roche Ltd
    6. Fulgent Genetics, Inc.
    7. Illumina, Inc.
    8. Invitae Corporation
    9. Konica Minolta, Inc.
    10. Laboratory Corporation of America Holdings
    11. Myriad Genetics, Inc.
    12. OPKO Health, Inc.
    13. QIAGEN N.V.
    14. Quest Diagnostics Incorporated
    15. Thermo Fisher Scientific Inc.

    Next-Generation Gynecological Cancer Diagnostics Market Share of Key Players

    Next-Generation Gynecological Cancer Diagnostics Market Share of Key Players

    Recent Developments

    • Jun 2022, Agilent Announces New Oligonucleotide Analysis Software for Biopharma Research.

    Next-Generation Gynecological Cancer Diagnostics Market Segmentations

    By Technology (2018-2030)

    • Next-Generation Sequencing
    • qPCR & Multiplexing
    • Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
    • Protein Microarrays
    • DNA Microarrays

    By Application (2018-2030)

    • Biomarker Development
    • CTC Analysis
    • Proteomic Analysis
    • Epigenetic Analysis
    • Genetic Analysis

    By Cancer Type (2018-2030)

    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Cervical Cancer

    By Function  (2018-2030)

    • Therapeutic Monitoring
    • Companion Diagnostics
    • Prognostics
    • Cancer Screening
    • Risk Analysis

    Frequently Asked Questions (FAQs)

    What is the growth rate for the Next-Generation Gynecological Cancer Diagnostics Market?
    Next-Generation Gynecological Cancer Diagnostics Market size will grow at approx. CAGR of 10.68% during the forecast period.
    Some of the top industry players in Next-Generation Gynecological Cancer Diagnostics Market are, Agilent Technologies, Inc., ARUP Laboratories, BGI Genomics, CENTOGENE N.V., F. Hoffmann-La Roche Ltd, Fulgent Genetics, Inc., Illumina, Inc., Invitae Corporation, Konica Minolta, Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., OPKO Health, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., etc.
    North America has held a dominant position in the Next-Generation Gynecological Cancer Diagnostics Market, with the largest market share.
    The Asia Pacific region has experienced the highest growth rate in the Next-Generation Gynecological Cancer Diagnostics Market.
    The global Next-Generation Gynecological Cancer Diagnostics Market report is segmented as follows: By Technology, By Application, By Cancer Type, By Function


    We are featured on :